Propoxyphene, (R,R)- | 745736-89-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: Propoxyphene, (R,R)-
• 英文别名: [(2R,3R)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate
• CAS: 745736-89-4
• 化学式: C₂₂H₂₉NO₂
• 分子量: 339.5
• InChiKey: XLMALTXPSGQGBX-XMSQKQJNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  25
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• STRUCTURALLY MODIFIED OPIOIDS FOR PREVENTION AND TREATMENT OF DISEASES AND CONDITIONS
  申请人：University of Padova

  公开号：EP3917619A1

  公开（公告）日：2021-12-08
• US4012525A
  申请人：——

  公开号：US4012525A

  公开（公告）日：1977-03-15
• [EN] NARCOTIC-NSAID ION PAIRS<br/>[FR] PAIRS D'IONS NARCOTIQUE/AINS
  申请人：AAIPHARMA INC

  公开号：WO2005086960A2

  公开（公告）日：2005-09-22

  The present invention provides an ion pair compound of the formula [narcotic]+[A]-, wherein [narcotic]+ represents at least one cation of at least one narcotic agent or one or more stereochemical isomers thereof and [A]- represents at least one anion of at least one NSAID or one or more stereochemical isomers thereof. An example of the ion pair compound is propoxyphene diclofenate. The ion pair compounds, or their pharmaceutical compositions, are useful in methods of treating a wide variety of conditions that indicate analgesics, anti-inflammatory agents, or both. Under the conditions prescribed for their use, the ion pair compounds exhibit poor or complete insolubility but excellent chemical stability in low pH environments, such as those found in the stomach. The ion pair compounds readily dissolve and dissociate in higher pH environments such as the small intestine to release the constituent narcotic and NSAID.
• [EN] STRUCTURALLY MODIFIED OPIOIDS FOR PREVENTION AND TREATMENT OF DISEASES AND CONDITIONS<br/>[FR] OPIOÏDES À MODIFICATION STRUCTURALE POUR LA PRÉVENTION ET LE TRAITEMENT DE MALADIES ET DE PATHOLOGIES
  申请人：UNIV OF PADOVA

  公开号：WO2020159587A1

  公开（公告）日：2020-08-06

  Aspects of the present invention are directed to structurally modified opioids (SMOs) that result in improved modulating activity at the NMDAR and improved PK and PD parameters over existing drugs with NMDAR modulating activity. The structural modifications of an opioid or opioid enantiomer that result in the SMOs can be obtained by starting the synthetic process de novo; by modifying the synthetic process for the opioid at any intermediate step during the synthesis of the racemate or of one enantiomer; or by modifying the structure of the opioid or opioid enantiomer after the synthesis. The nitric acid ester substitutions are of particular relevance, especially when associated to deuterated substitutions and/or halogen substitutions.